Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05208229

The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA) — WB-LuPSMA  

Metastatic Castration Resistant Prostate Cancer (mCRPC) Clinical Trial

Official title:
The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lu-PSMA

Clinical Trial Summary

The role of WB-MRI in the evaluation of prostate cancer patients treated with Lu-PSMA

Clinical Trial Description

Multicentric, observational, single arm, prospective, study. All patients will undergo imaging assessments according to clinical practice or to Lu-PSMA Tumor Institute of Romagna (IRST) 185.03 protocol, as follows: - Baseline, before the treatment with Lu-PSMA, CT and WB-MRI will be performed - At the end of treatment with Lu-PSMA, CT and WB-MRI will be performed - In post-treatment follow-up every 4 months, until progression or for 1 year, CT and WB-MRI will be performed. Patients participating in this observational study will not be subjected to any additional procedure that falls outside the clinical practice or the study 185.03 Lu-PSMA trial at IRST. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05208229
Study type Observational
Source Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Contact
Status Terminated
Phase
Start date October 25, 2022
Completion date October 25, 2022
View Details
See also
  Status Clinical Trial Phase
Suspended NCT05425862 - Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1
Active, not recruiting NCT03480646 - ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1/Phase 2
Recruiting NCT03874884 - 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1
Terminated NCT03549000 - A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. Phase 1
Completed NCT05701007 - Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Terminated NCT04052204 - Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03724747 - Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1
Completed NCT04516161 - EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
Withdrawn NCT02130947 - Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide N/A